Eliem Therapeutics Inc (ELYM)
$7.39
Performance
- $7.38$7.78$7.39
0.14%
Downside
Day's Volatility :5.08%
Upside
4.95%
- $2.35$11.55$7.39
68.2%
Downside
52 Weeks Volatility :79.65%
Upside
36.02%
Returns
| Period | Eliem Therapeutics Inc | Index (Russel 2000) |
|---|---|---|
3 Months | -16.78% | 0.0% |
6 Months | 161.59% | 0.0% |
1 Year | 178.87% | 0.0% |
3 Years | -74.17% | -22.3% |
Highlights
Market Capitalization | 495.6M |
Book Value | $3.33 |
Earnings Per Share (EPS) | -2.22 |
Wall Street Target Price | 4.5 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -24.54% |
Return On Equity TTM | -38.35% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -2.22 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 0.0 |
EPS Estimate Next Year | 0.0 |
EPS Estimate Current Quarter | 0.0 |
EPS Estimate Next Quarter | 0.0 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Downside of 39.11%
Technicals Summary
Sell
Neutral
Buy
Eliem Therapeutics Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Eliem Therapeutics Inc | 22.15% | 161.59% | 178.87% | -74.17% | -53.52% |
 Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
 Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
 Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
 Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Eliem Therapeutics Inc | NA | NA | NA | 0.0 | -0.38 | -0.25 | NA | 3.33 |
Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Eliem Therapeutics Inc | Sell | $495.6M | -53.52% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Eliem Therapeutics Inc
Vs NVO
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 143.4%
Institutional Holdings
RA Capital Management, LLC
46.85%Deep Track Capital, LP
5.82%Samsara BioCapital, LLC
4.86%HHG PLC
4.85%Boxer Capital LLC
3.88%Affinity Asset Advisors, LLC
2.49%
Company Information
eliem therapeutics is a biotechnology company delivering therapies that empower patients to live on their own terms. headquartered in seattle with r&d primarily in cambridge, uk, eliem channels its experience, energy, and passion for improving patients’ quality of life by developing and commercializing potentially “best-in-class” drug candidates to treat neuronal excitability disorders. these conditions—such as chronic pain, depression, epilepsy, and anxiety—cause deep suffering for tens of millions of people each day. at its core, the eliem team is motivated by the promise of helping patients live happier, more fulfilling lives. eliem is a publicly traded company (nasdaq: elym) read our community guidelines here: https://eliemtx.com/community-engagement-guidelines/
Organization | Eliem Therapeutics Inc |
Employees | 9 |
CEO | Dr. Aoife M. Brennan BAO, BCh, M.D., MB, MMSc |
Industry | Miscellaneous |
Discover More
A Spac I Acquisition Corp
$7.39
-2.38%
Keyarch Acquisition Corp
$7.39
-2.38%
Connexa Sports Technologies Inc
$7.39
-2.38%
Us Value Etf
$7.39
-2.38%
First Wave Biopharma Inc
$7.39
-2.38%
Global X Msci Next Emerging
$7.39
-2.38%
Fat Projects Acquisition Corp
$7.39
-2.38%
Capital Link Global Fintech
$7.39
-2.38%
Applied Uv Inc
$7.39
-2.38%